Glaukos Corporation
GKOS
Kedudukan dalam Saham
#2087
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Harga Saham
$166.79
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$9.84B
Perubahan (1 hari)
1.44%
Perubahan (1 tahun)
109.88%
Negara
US
Perdagangan Glaukos Corporation (GKOS)
Kategori
Healthcare
Pendapatan untuk Glaukos Corporation (GKOS)
Pendapatan pada Jun 2026 TTM: $-192.83M
Menurut laporan kewangan terkini Glaukos Corporation, pendapatan semasa syarikat ialah $-192.83M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-133.73M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-98.43M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Glaukos Corporation dari 2012 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-192.83M | 32.44% |
| 2024 | $-145.60M | 8.88% |
| 2023 | $-133.73M | 35.86% |
| 2022 | $-98.43M | 99.79% |
| 2021 | $-49.27M | -62.77% |
| 2020 | $-132.31M | 164.44% |
| 2019 | $-50.04M | 304.56% |
| 2018 | $-12.37M | -1,236,900.00% |
| 2017 | $1.00K | -99.98% |
| 2016 | $4.57M | -111.92% |
| 2015 | $-38.29M | 172.73% |
| 2014 | $-14.04M | -1.28% |
| 2013 | $-14.22M | -35.41% |
| 2012 | $-22.02M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $7.51B | -3,995.08% |
US
|
|
| $5.56B | -2,984.88% |
IE
|
|
| $5.15B | -2,769.67% |
US
|
|
| $3.86B | -2,102.25% |
US
|
|
| - | - |
DE
|
